Peptides / Growth hormone axis

Natural peptide · 191 amino acids · 22,124.8 Da

HGH (somatotropin)

ApprovedBanned in sport

HGH (human growth hormone, somatotropin) is approved in the US and EU as recombinant medicines for growth hormone deficiency and some growth disorders, and banned in sport. Studies in people tested it on height growth, bone, body composition, IGF-1 levels and blood sugar. PepBank shows 1,034 results on HGH from 120 studies in people, and 74 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as hGH, Growth hormone, Human growth hormone, Somatotropin, Somatropin, Genotropin and 5 more

First 40 of 191 amino acids2 changed amino acids

Evidence level: Large trials in people1,034 of 1,108 results come from studies in people, including randomized trials.

Results in people

1,034

93% of 1,108 results

Results in animals

7% of 1,108 results

Results in lab cells

0% of 1,108 results

From computer models

0% of 1,108 results

Overview

HGH (somatotropin) at a glance

What it is	Natural peptide, 191 amino acids
Approval	Approved in the US and EU (Genotropin)
In sport	Banned in sport (WADA S2.2.3)
Studies	140 studies with results. 137 of them gave HGH, with 1,108 results. 1,034 in people74 in animals
Best study in people	Randomized controlled trial with 343 people (2017)
Clinical trials	358 registered: 32 active or planned, 102 with posted results
Community use	Genotropin replacement in adults with confirmed adult-onset or childhood-onset growth hormone deficiency

The science

What is HGH?

Somatropin is recombinant human growth hormone with the mature 191-residue human sequence.

191

Amino acids in one chain

The history of HGH

1966
The oldest paper on HGH in PepBank is from 1966.
2004May
A registered trial of HGH started (NCT00082628).

HGH (somatotropin) structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 191 amino acidsFrom the first amino acid to the last

F1PTIP5LS+RLF10−DNAML15+RAH+RL20HQLAF25−DTYQ−E30F−E−EAY35IP+K−EQ40+KYSFL45QNPQT50SLCFS55−ESIPT60PSN+R−E65−ETQQ+K70SNL−EL75L+RISL80LLIQS85WL−EPV90QFL+RS95VFANS100LVYGA105S−DSNV110Y−DLL+K115−DL−E−EG120IQTLM125G+RL−E−D130GSP+RT135GQIF+K140QTYS+K145F−DTNS150HN−D−DA155LL+KNY160GLLYC165F+R+K−DM170−D+KV−ET175FL+RIV180QC+RSV185−EGSCG190F

Darker means more water-repelling+ and − show charge in the bodyOutlined: changed amino acid

Structure

HGH (somatotropin) is a natural peptide of 191 amino acids, with no ring, 2 disulfide bonds, 2 changed amino acids.

Formula

C₉₉₀H₁₅₂₈N₂₆₂O₃₀₀S₇

Molecular weight

22,124.8 g/mol

CAS number

12629-01-5

Target

Growth hormone receptor (gene GHR): agonistEvidence: ChEMBL mechanism annotation, supported by the approved-drug label

Development

Multiple (Eli Lilly, Pfizer, Novo Nordisk, Sandoz, Ferring and others). Highest phase: past the trial stage (see status).

Identifiers

ChEMBL CHEMBL1201621, UNII NQX9KB6PCL, DrugBank DB00052, KEGG D02691, IUPHAR 4943, UniProt P01241, PDB 1HWG

Full sequence, SMILES and InChIKey

Three-letter sequence
H-Phe-Pro-Thr-Ile-Pro-Leu-Ser-Arg-Leu-Phe-Asp-Asn-Ala-Met-Leu-Arg-Ala-His-Arg-Leu-His-Gln-Leu-Ala-Phe-Asp-Thr-Tyr-Gln-Glu-Phe-Glu-Glu-Ala-Tyr-Ile-Pro-Lys-Glu-Gln-Lys-Tyr-Ser-Phe-Leu-Gln-Asn-Pro-Gln-Thr-Ser-Leu-Cys-Phe-Ser-Glu-Ser-Ile-Pro-Thr-Pro-Ser-Asn-Arg-Glu-Glu-Thr-Gln-Gln-Lys-Ser-Asn-Leu-Glu-Leu-Leu-Arg-Ile-Ser-Leu-Leu-Leu-Ile-Gln-Ser-Trp-Leu-Glu-Pro-Val-Gln-Phe-Leu-Arg-Ser-Val-Phe-Ala-Asn-Ser-Leu-Val-Tyr-Gly-Ala-Ser-Asp-Ser-Asn-Val-Tyr-Asp-Leu-Leu-Lys-Asp-Leu-Glu-Glu-Gly-Ile-Gln-Thr-Leu-Met-Gly-Arg-Leu-Glu-Asp-Gly-Ser-Pro-Arg-Thr-Gly-Gln-Ile-Phe-Lys-Gln-Thr-Tyr-Ser-Lys-Phe-Asp-Thr-Asn-Ser-His-Asn-Asp-Asp-Ala-Leu-Leu-Lys-Asn-Tyr-Gly-Leu-Leu-Tyr-Cys-Phe-Arg-Lys-Asp-Met-Asp-Lys-Val-Glu-Thr-Phe-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-OH (disulfides Cys53-Cys165, Cys182-Cys189)

See charge, composition and 3D structure on the Scientific page

The evidence

What HGH studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Large trials in people1,034 of 1,108 results come from studies in people, including randomized trials.

Growth hormone and growth

236 results · 217 in people · 19 animal

In children with growth hormone deficiency, daily rhGH increased height velocity less than Jintrolong. European journal of endocrinology, 2017

Top results

In children with growth hormone deficiency, daily rhGH increased height velocity less than Jintrolong. (European journal of endocrinology, 2017)
In children with chronic renal failure, standardized height improved with rhGH compared with placebo. (The Journal of pediatrics, 1994)
In GH-deficient adolescents, high-dose GH increased near-adult height more than standard-dose GH. (The Journal of clinical endocrinology and metabolism, 2000)

Weight and appetite

160 results · 151 in people · 9 animal

In short children born SGA, changes in BMI, skinfolds, blood pressure and lipids did not differ between GH doses. The Journal of clinical endocrinology and metabolism, 2000

Top results

In short children born SGA, changes in BMI, skinfolds, blood pressure and lipids did not differ between GH doses. (The Journal of clinical endocrinology and metabolism, 2000)
In patients with HIV-associated wasting, GH increased weight more than placebo. (Annals of internal medicine, 1996)
In adults on hemodialysis, hGH increased lean body mass more than placebo. (Journal of the American Society of Nephrology, 2007)

Bones and joints

126 results · 115 in people · 11 animal

In adults with GH deficiency, GH increased osteocalcin versus controls. Journal of bone and mineral research, 2002

Top results

In adults with GH deficiency, GH increased osteocalcin versus controls. (Journal of bone and mineral research, 2002)
In severely burned children, increased bone mineral content during GH treatment was linked to higher parathormone levels. (Annals of surgery, 2001)
In GH-deficient patients, urinary calcium/creatinine rose temporarily with GH and returned to baseline at 9 months. (The Journal of clinical endocrinology and metabolism, 1996)

Blood sugar

85 results · 85 in people

In short children born small for gestational age, metabolic changes did not differ between GH doses. Clinical endocrinology, 2001

Top results

In short children born small for gestational age, metabolic changes did not differ between GH doses. (Clinical endocrinology, 2001)
In GH-deficient adolescents, hemoglobin A1c did not differ between high and standard GH doses. (The Journal of clinical endocrinology and metabolism, 2000)
In hypopituitary adults, fasting glucose was similar with GH and placebo. (The Journal of clinical endocrinology and metabolism, 1995)

Cholesterol and blood fats

76 results · 76 in people

In adults on hemodialysis, hGH increased HDL cholesterol compared with placebo. Journal of the American Society of Nephrology, 2007

Top results

In adults on hemodialysis, hGH increased HDL cholesterol compared with placebo. (Journal of the American Society of Nephrology, 2007)
In obese women during diet restriction, GH did not increase adipose tissue HSL activity more than placebo. (Metabolism: clinical and experimental, 2000)
In postmenopausal women with abdominal obesity, GH reduced total cholesterol compared with placebo. (The Journal of clinical endocrinology and metabolism, 2005)

Daily life and fitness

62 results · 62 in people

In adults with GH deficiency, growth hormone did not significantly change strength versus placebo. The Journal of clinical endocrinology and metabolism, 2004

Top results

In adults with GH deficiency, growth hormone did not significantly change strength versus placebo. (The Journal of clinical endocrinology and metabolism, 2004)
In adults with GH deficiency, growth hormone did not significantly change quality of life versus placebo. (The Journal of clinical endocrinology and metabolism, 2004)
In children born SGA, self-perception scores improved from the start of growth hormone treatment. (The Journal of clinical endocrinology and metabolism, 2004)

HGH has 2,837 linked papers. PepBank read up to 120 of the most-cited studies that gave it to people, up to 20 other studies, and the main trials.

All 140 HGH studies by area Open the Scientific page

Key HGH studies

Studies in people come first, then studies in animals and in the lab.

People
Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies
Luo et al. 2017 · European journal of endocrinology · 343 people · cited by 89
4 results
People
Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study
Deal et al. 2022 · The Journal of clinical endocrinology and metabolism · 228 people · cited by 95
5 results
People
Growth hormone (GH) treatment to final height in children with idiopathic short stature: evidence for a dose effect
Wit et al. 2005 · The Journal of pediatrics · 142 people · cited by 89
10 results
People
Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk
Feldt-Rasmussen et al. 2007 · Journal of the American Society of Nephrology : JASN · 139 people · cited by 77
8 results
People
Human growth hormone for poor responders: a randomized placebo-controlled trial provides no evidence for improved live birth rate
Norman et al. 2019 · Reproductive biomedicine online · 113 people · cited by 54
4 results

All 140 HGH (somatotropin) studies

HGH clinical trials

ClinicalTrials.gov lists 358 trials of HGH. 32 are active or planned, and 102 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis

Phase 3terminated712 planned

Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients

Phase 3completed326 people

Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature

Phase 3completed316 people

All 123 HGH (somatotropin) trials

Status and safety

Is HGH approved?

FDA

United States

Approved

An approved medicine contains it.

EMA

European Union

Approved

An approved medicine contains it.

WADA

Sport

Banned

On the 2026 Prohibited List, section S2.2.3.

Yes. Approved in the US and EU (Genotropin). The FDA label for Genotropin says: “Replacement in adults with adult-onset or childhood-onset GHD” Banned in sport (WADA S2.2.3).

Laws and labels change, so check the regulator for the current status.

HGH side effects and safety

PepBank has 110 safety results from studies of HGH. 108 of them come from studies in people.

Safety results from studies (110)

In GH-deficient adults, adverse effects occurred in 84% with GH versus 75% with placebo. (The Journal of clinical endocrinology and metabolism, 1998)
In adults on hemodialysis, clinically relevant adverse events did not differ between hGH and placebo groups. (Journal of the American Society of Nephrology, 2007)
In children with growth hormone deficiency, adverse event rates were comparable with daily rhGH and Jintrolong. (European journal of endocrinology, 2017)
In critically ill multinational patients, GH increased in-hospital mortality compared with placebo. (The New England journal of medicine, 1999)
In children with growth hormone deficiency, mild to moderate adverse event proportions were similar with somatropin and somatrogon. (The Journal of clinical endocrinology and metabolism, 2022)
In patients with HIV-associated wasting, clinical events did not differ significantly between GH and placebo. (Annals of internal medicine, 1996)
In healthy older men, GH recipients reported more side-effect incidents than placebo recipients. (Annals of internal medicine, 1996)
In renal transplant children, kidney filtration changes did not differ significantly between rhGH and controls. (Archives of disease in childhood, 1998)
In GH-deficient adolescents, discontinuation frequency was the same with high and standard GH doses. (The Journal of clinical endocrinology and metabolism, 2000)
In children with idiopathic short stature, safety measures did not differ by GH dose. (The Journal of pediatrics, 2005)
In severe burn patients, hyperglycemia occurred more often with HGH than oxandrolone. (Burns, 1999)
In elderly men, more participants withdrew from the hGH group than untreated controls, mostly for reasons probably unrelated to hGH. (Clinical endocrinology, 1993)
In children with renal transplants, no first-year rejection episodes occurred with rhGH versus three episodes in controls. (Kidney international, 2002)
In short children born SGA, the insulin increase after growth hormone cessation resembled the increase in untreated children. (The Journal of clinical endocrinology and metabolism, 2002)
In severely burned children, mortality was 2% with rhGH and saline placebo in controlled studies. (Annals of surgery, 1998)
In growth hormone-deficient patients with heart failure who received growth hormone, no major adverse events were reported. (JACC. Heart failure, 2013)
No short children born small for gestational age developed diabetes during GH treatment. (Clinical endocrinology, 2001)
In girls with Turner syndrome, GH treatment was well tolerated at all three doses studied. (The Journal of clinical endocrinology and metabolism, 1999)
In adults with GH deficiency, 25 patients (40%) had no side-effects during GH replacement. (Clinical endocrinology, 1995)
In GH-deficient men, side effects required GH dose reduction in 18 of 46 patients. (The Journal of clinical endocrinology and metabolism, 1996)
In children with chronic renal insufficiency, no adverse effects of GH therapy were reported. (Pediatric nephrology, 2000)
In elderly GH-deficient patients, GH side effects were mild and mostly linked to fluid retention. (The Journal of clinical endocrinology and metabolism, 2000)
In children with Noonan's syndrome, heart wall thickness at the mitral valve did not increase during rhGH treatment. (The Journal of clinical endocrinology and metabolism, 1996)
In participants with chronic brain injury, GH replacement produced no untoward treatment side effects. (Journal of neurotrauma, 2010)

See every safety result on the Scientific page

Doses studied (40 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
0.25 mg/kg/week daily	Human	human	Not reported	25 weeks	Randomized trial in people · n = 343	Luo 2017
0.24 mg/kg/week once daily	Human	human	Not reported	12 months	Randomized trial in people · n = 228	Deal 2022
20, 35, or 50 microg/kg per d	Human	human	Not reported	6 months	Randomized trial in people · n = 139	Feldt-Rasmussen 2007
0.7 mg/kg x week	Human	human	Not reported	Not reported	Randomized trial in people · n = 75	Mauras 2000
2 IU daily	Human	human	subcutaneous	minimum of 12 weeks	Randomized trial in people · n = 50	Osterziel 1998
5 mg per day for one week, then 1.5 mg per day	Human	human	Subcutaneous	Four months	Randomized trial in people · n = 34	Slonim 2000
0.125 U/kg per week for 1 month, then 0.25 U/kg per week for 5 months	Human	human	Not reported	6 months	Randomized trial in people	Cuneo 1998
0.0125 mg/kg.d, adjusted to 0.025 or 0.00625 mg/kg.d	Human	human	Not reported	12 months	Randomized trial in people	Hoffman 2004
0.37 mg/kg/week	Human	human	Not reported	Mean 6.5 years	Randomized trial in people	Wit 2005
0.10 +/- 0.02 mg/kg daily	Human	human	Not reported	Until intensive care discharge or maximum 21 days	Randomized trial in people · n = 285	Takala 1999
0.1 mg/kg per day (average 6 mg/d)	Human	human	Not reported	12 weeks	Randomized trial in people · n = 178	Schambelan 1996
0.067 mg/kg.d	Human	human	Not reported	2.7 +/- 0.6 yr	Randomized trial in people · n = 124	Carel 2003
0.18 IU/kg per week	Human	human	Not reported	24 months	Randomized trial in people · n = 100	Bex 2002
6 IU/m2 x day	Human	human	Not reported	6 years	Randomized trial in people · n = 79	Sas 2000
3 or 6 IU/m2 body surface/day	Human	human	Not reported	6 years	Randomized trial in people · n = 79	Sas 2000
6 IU/(m(2) body surface.day)	Human	human	Not reported	6 years	Randomized trial in people · n = 78	Sas 2001
target 12 micrograms/kg x day	Human	human	sc daily at bedtime	6 months	Randomized trial in people · n = 68	Johannsson 1996
0.074 mg/kg three times per week	Human	human	subcutaneous	at least 6 months	Randomized trial in people · n = 62	Leschek 2004
6 IU/m(2).d	Human	human	Not reported	7.8 (1.7) yr	Randomized trial in people · n = 54	Van 2003
0.03 mg/kg three times a week	Human	human	Not reported	6 months	Randomized trial in people · n = 52	Papadakis 1996
0.2 or 0.3 IU/kg daily	Human	human	sc	2 yr	Randomized trial in people · n = 50	de 1996
0.2 mg/kg/day	Human	human	subcutaneous or intramuscular injection	Not reported	Randomized trial in people · n = 46	Gilpin 1994
starting 10 +/- 0.3 micrograms/kg per day; mean 4 +/- 2 micrograms/kg per day	Human	human	Not reported	18 months	Randomized trial in people · n = 40	Baum 1998
0.67 mg/d	Human	human	Not reported	12 months	Randomized trial in people · n = 40	Franco 2005
0.04 +/- 0.01 IU/kg daily	Human	human	Not reported	6 months	Randomized trial in people · n = 40	Beshyah 1995
6.0 IU/m2/day	Human	human	Not reported	Two years	Randomized trial in people · n = 35	Kamp 2002
Starting dose 10 microg/kg x day, subsequently adjusted	Human	human	Not reported	3 months	Randomized trial in people · n = 34	Amato 2000
Initial daily dose 10 micrograms/kg, reduced by 25% if IGF-1 elevated	Human	human	Not reported	18 months	Randomized trial in people · n = 32	Baum 1996
9.5 micrograms/kg daily	Human	human	Not reported	9 months	Randomized trial in people · n = 30	Johannsson 1997
1 mg/m(2)/day	Human	human	Not reported	12 months	Randomized trial in people · n = 29	Festen 2008
6.25 microg/kg lean body mass for 1 month, then 12.5 microg/kg lean body mass	Human	human	Not reported	3 months	Randomized trial in people · n = 28	Woodhouse 1999
1 mg/m(2)/day	Human	human	Not reported	1 year	Randomized trial in people · n = 25	Myers 2007
mean maximum daily dose 1.4 ± 0.12 mg/d	Human	human	Not reported	12 weeks	Randomized trial in people · n = 21	Fazeli 2010
0.25 IU/kg/week	Human	human	Not reported	3 and 6 months	Randomized trial in people · n = 20	Vandeweghe 1993
0.1 mg/kg/day	Human	human	continuous intravenous infusion	second, third, and fourth days after admission	Randomized trial in people · n = 20	Voerman 1992
66.7 microgram/kg three times weekly	Human	human	subcutaneous	6 months	Randomized trial in people · n = 20	Johannsson 1999
2 IU/m2 daily	Human	human	subcutaneous	4 months	Randomized trial in people · n = 20	Schlemmer 1991
Up to 0.25 U/kg/week in daily doses	Human	human	Not reported	3 months	Randomized trial in people · n = 20	Florkowski 1996
0.02 mg/kg BW.day	Human	human	sc	10 weeks	Randomized trial in people · n = 18	Taaffe 1994
0.02 mg/kg BW.day	Human	human	sc	10 weeks	Randomized trial in people · n = 18	Taaffe 1996

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

The official US label supports Genotropin replacement in adults with growth hormone deficiency. This record describes one selected label regimen.

Reported routines and cautions

What people use it for

Genotropin replacement in adults with confirmed adult-onset or childhood-onset growth hormone deficiencyS1

Reported regimens

Regimens that community sources report for Somatotropin. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Initial non-weight-based Genotropin replacement in adults with confirmed adult-onset or childhood-onset growth hormone deficiency. Formulation: lyophilized somatropin in a two-chamber cartridge after reconstitution.Official label dosing of an approved product	subcutaneous injectionThe label permits the thigh, buttocks, or abdomen. Rotate injection sites daily. Do not inject intravenously.	0.15 to 0.3 mg per day	The label divides the weekly dose into 6 or 7 subcutaneous injections.	Not stated	Single official US label source.	S1

Cautions

The label contraindicates active malignancy, hypersensitivity to somatropin or excipients, and active proliferative or severe non-proliferative diabetic retinopathy. It contraindicates pharmacologic amounts during acute critical illness after specified surgery or trauma, or during acute respiratory failure. The safety of continued replacement during these illnesses is not established. This list is incomplete.S1
The label requires monitoring for glucose intolerance, intracranial hypertension, fluid retention, thyroid dysfunction, and reduced cortisol or increased glucocorticoid requirements.S1

Status notes

EMA authorises Omnitrope, which contains somatropin. Omnitrope is a separate branded product from the selected Genotropin regimen.S2

Community sources

S1Genotropin US prescribing information (opens in a new tab)dailymed.nlm.nih.gov
S2EMA regulatory information (opens in a new tab)ema.europa.eu

Gaps

This independent check assessed one official label regimen. It did not assess a separate non-vendor community regimen. The label includes other patient groups, dosing methods, device instructions, and storage conditions. No fixed treatment duration is recorded here.

Questions and more

Ask a question about HGH

The answer links to every study it uses.

What does the evidence say about HGH?Is HGH tested in people?Compare with GHRP-6 Compare with IGF-1 LR3

Sources

Database: PepBank data for HGH (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about HGH

HGH (somatotropin)

ApprovedBanned in sport

Also known as hGH, Growth hormone, Human growth hormone, Somatotropin, Somatropin, Genotropin and 5 more

What it is

Natural peptide, 191 amino acids

Approval

Approved in the US and EU (Genotropin)

In sport

Banned in sport (WADA S2.2.3)

Studies

140 studies with results. 137 of them gave HGH, with 1,108 results.
1,034 in people74 in animals

Best study in people

Randomized controlled trial with 343 people (2017)

Clinical trials

358 registered: 32 active or planned, 102 with posted results

Community use

Genotropin replacement in adults with confirmed adult-onset or childhood-onset growth hormone deficiency

Dose as reported

Class

Species

Route

Duration

Design

Source

0.25 mg/kg/week daily

Human

human

Not reported

25 weeks

Randomized trial in people · n = 343

Luo 2017

0.24 mg/kg/week once daily

Human

human

Not reported

12 months

Randomized trial in people · n = 228

Deal 2022

20, 35, or 50 microg/kg per d

Human

human

Not reported

6 months

Randomized trial in people · n = 139

Feldt-Rasmussen 2007

0.7 mg/kg x week

Human

human

Not reported

Randomized trial in people · n = 75

Mauras 2000

2 IU daily

Human

human

subcutaneous

minimum of 12 weeks

Randomized trial in people · n = 50

Osterziel 1998

5 mg per day for one week, then 1.5 mg per day

Human

human

Subcutaneous

Four months

Randomized trial in people · n = 34

Slonim 2000

0.125 U/kg per week for 1 month, then 0.25 U/kg per week for 5 months

Human

human

Not reported

6 months

Randomized trial in people

Cuneo 1998

0.0125 mg/kg.d, adjusted to 0.025 or 0.00625 mg/kg.d

Human

human

Not reported

12 months

Randomized trial in people

Hoffman 2004

0.37 mg/kg/week

Human

human

Not reported

Mean 6.5 years

Randomized trial in people

Wit 2005

0.10 +/- 0.02 mg/kg daily

Human

human

Not reported

Until intensive care discharge or maximum 21 days

Randomized trial in people · n = 285

Takala 1999

0.1 mg/kg per day (average 6 mg/d)

Human

human

Not reported

12 weeks

Randomized trial in people · n = 178

Schambelan 1996

0.067 mg/kg.d

Human

human

Not reported

2.7 +/- 0.6 yr

Randomized trial in people · n = 124

Carel 2003

0.18 IU/kg per week

Human

human

Not reported

24 months

Randomized trial in people · n = 100

Bex 2002

6 IU/m2 x day

Human

human

Not reported

6 years

Randomized trial in people · n = 79

Sas 2000

3 or 6 IU/m2 body surface/day

Human

human

Not reported

6 years

Randomized trial in people · n = 79

Sas 2000

6 IU/(m(2) body surface.day)

Human

human

Not reported

6 years

Randomized trial in people · n = 78

Sas 2001

target 12 micrograms/kg x day

Human

human

sc daily at bedtime

6 months

Randomized trial in people · n = 68

Johannsson 1996

0.074 mg/kg three times per week

Human

human

subcutaneous

at least 6 months

Randomized trial in people · n = 62

Leschek 2004

6 IU/m(2).d

Human

human

Not reported

7.8 (1.7) yr

Randomized trial in people · n = 54

Van 2003

0.03 mg/kg three times a week

Human

human

Not reported

6 months

Randomized trial in people · n = 52

Papadakis 1996

0.2 or 0.3 IU/kg daily

Human

human

2 yr

Randomized trial in people · n = 50

de 1996

0.2 mg/kg/day

Human

human

subcutaneous or intramuscular injection

Not reported

Randomized trial in people · n = 46

Gilpin 1994

starting 10 +/- 0.3 micrograms/kg per day; mean 4 +/- 2 micrograms/kg per day

Human

human

Not reported

18 months

Randomized trial in people · n = 40

Baum 1998

0.67 mg/d

Human

human

Not reported

12 months

Randomized trial in people · n = 40

Franco 2005

0.04 +/- 0.01 IU/kg daily

Human

human

Not reported

6 months

Randomized trial in people · n = 40

Beshyah 1995

6.0 IU/m2/day

Human

human

Not reported

Two years

Randomized trial in people · n = 35

Kamp 2002

Starting dose 10 microg/kg x day, subsequently adjusted

Human

human

Not reported

3 months

Randomized trial in people · n = 34

Amato 2000

Initial daily dose 10 micrograms/kg, reduced by 25% if IGF-1 elevated

Human

human

Not reported

18 months

Randomized trial in people · n = 32

Baum 1996

9.5 micrograms/kg daily

Human

human

Not reported

9 months

Randomized trial in people · n = 30

Johannsson 1997

1 mg/m(2)/day

Human

human

Not reported

12 months

Randomized trial in people · n = 29

Festen 2008

6.25 microg/kg lean body mass for 1 month, then 12.5 microg/kg lean body mass

Human

human

Not reported

3 months

Randomized trial in people · n = 28

Woodhouse 1999

1 mg/m(2)/day

Human

human

Not reported

1 year

Randomized trial in people · n = 25

Myers 2007

mean maximum daily dose 1.4 ± 0.12 mg/d

Human

human

Not reported

12 weeks

Randomized trial in people · n = 21

Fazeli 2010

0.25 IU/kg/week

Human

human

Not reported

3 and 6 months

Randomized trial in people · n = 20

Vandeweghe 1993

0.1 mg/kg/day

Human

human

continuous intravenous infusion

second, third, and fourth days after admission

Randomized trial in people · n = 20

Voerman 1992

66.7 microgram/kg three times weekly

Human

human

subcutaneous

6 months

Randomized trial in people · n = 20

Johannsson 1999

2 IU/m2 daily

Human

human

subcutaneous

4 months

Randomized trial in people · n = 20

Schlemmer 1991

Up to 0.25 U/kg/week in daily doses

Human

human

Not reported

3 months

Randomized trial in people · n = 20

Florkowski 1996

0.02 mg/kg BW.day

Human

human

10 weeks

Randomized trial in people · n = 18

Taaffe 1994

0.02 mg/kg BW.day

Human

human

10 weeks

Randomized trial in people · n = 18

Taaffe 1996

Context

Route

Amount

How often

How long

Agreement

Sources

Initial non-weight-based Genotropin replacement in adults with confirmed adult-onset or childhood-onset growth hormone deficiency. Formulation: lyophilized somatropin in a two-chamber cartridge after reconstitution.Official label dosing of an approved product

subcutaneous injectionThe label permits the thigh, buttocks, or abdomen. Rotate injection sites daily. Do not inject intravenously.

0.15 to 0.3 mg per day

The label divides the weekly dose into 6 or 7 subcutaneous injections.

Not stated

Single official US label source.

HGH (somatotropin)

HGH (somatotropin) at a glance

What is HGH?

The history of HGH

HGH (somatotropin) structure and chemistry

What HGH studies show

Growth hormone and growth

Weight and appetite

Bones and joints

Blood sugar

Cholesterol and blood fats

Daily life and fitness

Key HGH studies

HGH clinical trials

Is HGH approved?

HGH side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about HGH

Related peptides

Sources

HGH (somatotropin)

HGH (somatotropin) at a glance

What is HGH?

The history of HGH

HGH (somatotropin) structure and chemistry

What HGH studies show

Growth hormone and growth

Weight and appetite

Bones and joints

Blood sugar

Cholesterol and blood fats

Daily life and fitness

Key HGH studies

HGH clinical trials

Is HGH approved?

HGH side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about HGH

Related peptides

Sources